Evaluation of Total and IgA-Specific Antibody Targeting Epstein-Barr Virus Glycoprotein 350 and Nasopharyngeal Carcinoma Risk
Evaluation of Total and IgA-Specific Antibody Targeting Epstein-Barr Virus Glycoprotein 350 and Nasopharyngeal Carcinoma Risk
复制标题
DOI：
10.1093/infdis/jiy250
复制
发表时间：
2018-09-15
影响因子：
6.4
通讯作者：
Hildesheim, Allan
中科院分区：
文献类型：
--
作者：
Coghill, Anna E.;Bu, Wei;Hildesheim, Allan
背景我们先前曾报道，针对EB病毒（EBV）糖蛋白350（gp 350），一种EBV疫苗候选人，高水平的抗体，对鼻咽癌（NPC）的遗传高危家庭从台湾的保护。目前的研究试图将这种关联扩展到一般人群。我们比较了台湾癌症筛检计划（1991-1992年招募的23943人）中35例鼻咽癌病例和81例无病对照的总抗体和IgA特异性gp 350抗体水平。荧光素酶免疫沉淀分析定量gp 350抗体。总EBVgp 350抗体水平并不高的个人谁保持无病相比，那些发展NPC（P = 0.11）。这种缺乏保护性gp 350相关性的情况在诊断≥ 5年的病例中持续存在（比值比[ OR] = 1.05; P = .91），
Background. We previously reported that higher levels of antibody targeting Epstein-Barr virus (EBV) glycoprotein350 (gp350), an EBV vaccine candidate, were protective against nasopharyngeal carcinoma (NPC) in genetically high-risk families from Taiwan. The current study attempted to extend this association to a general population cohort.Methods. We compared total and IgA-specific gp350 antibody levels in 35 incident NPC cases and 81 disease-free controls from the Cancer Screening Program in Taiwan (23 943 individuals recruited 1991-1992). Luciferase immunoprecipitation assays quantified gp350 antibody.Results. Total EBVgp350 antibody levels were not higher in individuals who remained disease free compared to those who developed NPC (P = .11). This lack of a protective gp350 association persisted for cases diagnosed = 5 years (odds ratio [ OR] = 1.05; P = .91) and